Advancing Precision Oncology in Japan: Domestic CDx Approvals & Diagnostic Innovation
- Lessons from domestic CDx approvals, such as BRAF, and integration of complex biomarkers including TME analysis
- Opportunities and challenges in Japan’s genomic medicine landscape, regulatory approval, and clinical adoption